Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – The 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics: Pediatric Allergy and Immunology

H.A. Brough, O. Kalayci, A. Sediva, E. Untersmayr, D. Munblit, P. Rodriguez del Rio, M. Vazquez-Ortiz, S. Arasi, M. Alvaro-Lozano, S. Tsabouri, E. Galli, B. Beken, P.A. Eigenmann

Research output: Contribution to journalArticlepeer-review

Abstract

While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and healthcare providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, and bronchodilators, increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic, and immunodeficient children should be sought according to usual treatment guidelines. This statement of the EAACI Section on Pediatrics puts forward six recommendations for the management of childhood allergies and immunodeficiencies based on six underlying facts and existing evidence. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Original languageEnglish
Pages (from-to)442-448
Number of pages7
JournalPediatr. Allergy Immunol.
Volume31
Issue number5
DOIs
Publication statusPublished - 2020

Keywords

  • allergy
  • asthma
  • biologics
  • children
  • coronavirus
  • corticosteroids
  • COVID-19
  • immunodeficiency
  • SARS-CoV-2
  • treatment
  • antiallergic agent
  • antiasthmatic agent
  • allergic disease
  • child
  • child health care
  • coronavirus disease 2019
  • disease predisposition
  • disease severity
  • high risk population
  • human
  • hygiene
  • immune deficiency
  • pandemic
  • practice guideline
  • priority journal
  • Review
  • risk factor
  • telemedicine
  • virus infection
  • adolescent
  • Betacoronavirus
  • Coronavirus infection
  • Europe
  • hypersensitivity
  • infant
  • organization
  • pediatrics
  • preschool child
  • procedures
  • virus pneumonia
  • Academies and Institutes
  • Adolescent
  • Child
  • Child, Preschool
  • Coronavirus Infections
  • Humans
  • Hypersensitivity
  • Immunologic Deficiency Syndromes
  • Infant
  • Pandemics
  • Pediatrics
  • Pneumonia, Viral
  • Practice Guidelines as Topic

Fingerprint Dive into the research topics of 'Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – The 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics: Pediatric Allergy and Immunology'. Together they form a unique fingerprint.

Cite this